Tarsus Pharmaceuticals (TARS) Long-Term Investments (2022 - 2026)

Tarsus Pharmaceuticals' Long-Term Investments history runs 5 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 29.0% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a 29.0% increase from a year earlier, with the FY2025 full-year figure at $3.9 million, up 29.0% from the prior year.
• Long-Term Investments held at $3.9 million in Q1 2026 per TARS's latest filing, from $3.9 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $3.9 million in Q4 2025 and bottomed at $157000.0 in Q3 2022.
• The 5-year median for Long-Term Investments is $3.0 million (2024), against an average of $1.9 million.
• Across the five-year window, Long-Term Investments surged 1328.57% in 2024 and changed 0.0% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $371000.0 in 2022, then soared by 70.08% to $631000.0 in 2023, then surged by 375.44% to $3.0 million in 2024, then increased by 29.0% to $3.9 million in 2025, then changed by 0.0% to $3.9 million in 2026.
• Per Business Quant, the three latest TARS Long-Term Investments figures stand at $3.9 million (Q1 2026), $3.9 million (Q4 2025), and $3.0 million (Q3 2025).